跳至主要内容
临床试验/NCT02901496
NCT02901496已完成不适用

The Role of Exercise Training Combined With Tocilizumab on Visceral and Epicardial Adipose Tissue and Gastric Emptying in a High Risk Population: an Exploratory Double-blind, Placebo-controlled Randomised Trial

Rigshospitalet, Denmark1 个研究点 分布在 1 个国家目标入组 83 人开始时间: 2016年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
83
试验地点
1
主要终点
Changes in visceral fat mass

研究概览

简要总结

Aim: Exercise training improves the risk of cardiometabolic diseases; yet the underlying mechanisms are unclear. Exercise induces release of IL-6 from skeletal muscle. Acute elevations in IL-6 improve lipid and glucose metabolism, the latter partly through a delayed gastric emptying. Physical inactivity causes accumulation of visceral fat (VAT). Visceral and epicardial adipose tissue (EAT) is more inflamed than subcutaneous adipose tissue. Thus, the investigators hypothesize that exercise-induced IL-6 mediates the exercise-induced reduction in EAT and VAT. Secondly, the investigators hypothesize that exercise-induced adaptations in glucose metabolism and gastric motility are dependent on IL-6. Finally the investigators hypothesise that both endurance and resistance exercise training reduce VAT and EAT.

Primary aim: To investigate the effects of exercise training on VAT and to determine to what extend IL-6 mediates this effect.

Secondary aims: 1) To determine whether 12 weeks of endurance and strength training can reduce the amount of EAT. 2) To study whether the effects of exercise on glucose metabolism and gastric emptying are dependent on IL-6.

Methods: Inclusion: 70 inactive men and women, >18 years, waist to height ratio > 0.5 and/or waist circumference ≥ 88 cm (women); waist circumference ≥ 102 cm (men) Design: A 12-week, double-blinded randomised, placebo-controlled exercise intervention study.

Intervention: Subjects will be randomised to one of five groups: i) Tocilizumab (IL-6 receptor antibody) and endurance training, ii) Placebo to Tocilizumab and endurance training, iii) Tocilizumab, no exercise iv) Placebo to Tocilizumab and no training, and v) Placebo to Tocilizumab, and resistance training. Tocilizumab/placebo dose will be administered (according to standard recommendations) before the first training session, and maintained during the 12-week training program. Training will be supervised to ensure intensity and compliance. Subjects will be instructed not to change eating habits and informed that this study does not aim for a weight loss.

Statistical considerations: Study investigators are blinded to treatment allocation. Dropouts will be replaced. A sample size of 70 subjects is needed to detect a 10% change in visceral adipose, with a power of 80% and a significance level of 0.05.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men and women
  • Sedentary
  • Waist to height ratio ≥ ½ and/or waist circumference ≥ 88 cm (women); waist circumference ≥ 102 cm (men)
  • Age ≥ 18 y

排除标准

  • Pregnancy
  • Diagnosed with diabetes (HbA1c ≥ 48 mmol/mol or fasting glucose ≥ 7.0 mmol/l)
  • Diagnosed with ischemic heart disease
  • Atrial fibrillation
  • Treatment with biologic rheumatic drugs, systemic prednisolone or other immunosuppressive treatments
  • Health conditions that prevents individuals from participating in the exercise training intervention e.g. severe obesity
  • Patients who cannot undergo MRI scans (e.g. kidney disease, metallic implants or claustrophobia)

研究组 & 干预措施

Endurance exercise + infusion of Tocilizumab

Experimental

Endurance exercise training + monthly infusion of Tocilizumab

干预措施: Endurance Exercise Training (Behavioral)

Endurance exercise + infusion of Tocilizumab

Experimental

Endurance exercise training + monthly infusion of Tocilizumab

干预措施: Tocilizumab (Drug)

Endurance exercise + infusion of placebo

Experimental

Endurance exercise training + monthly infusion of placebo

干预措施: Endurance Exercise Training (Behavioral)

Endurance exercise + infusion of placebo

Experimental

Endurance exercise training + monthly infusion of placebo

干预措施: Placebo (Drug)

No exercise + infusion of Tocilizumab

Experimental

No exercise + monthly infusion of Tocilizumab

干预措施: No Exercise (Behavioral)

No exercise + infusion of Tocilizumab

Experimental

No exercise + monthly infusion of Tocilizumab

干预措施: Tocilizumab (Drug)

No exercise + infusion of placebo

Placebo Comparator

No exercise training + monthly infusion of placebo

干预措施: No Exercise (Behavioral)

No exercise + infusion of placebo

Placebo Comparator

No exercise training + monthly infusion of placebo

干预措施: Placebo (Drug)

Resistance exercise + infusion of placebo

Experimental

Resistance exercise training + monthly infusion of placebo

干预措施: Resistance Exercise Training (Behavioral)

Resistance exercise + infusion of placebo

Experimental

Resistance exercise training + monthly infusion of placebo

干预措施: Placebo (Drug)

结局指标

主要结局

Changes in visceral fat mass

时间窗: 0, 12 weeks

Visceral fat mass will be measured by MRI before and after the intervention. Difference in change in visceral fat mass from baseline to 12 weeks follow up will be compared between group: Endurancetraining + tocilizumab and group: Endurancetraining + placebo.

次要结局

  • Epicardial adipose tissue(0, 12 weeks)
  • Gastric emptying(0, 12 weeks)
  • Changes in visceral fat mass(0, 12 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Louise Lang Lehrskov

MD, PhD student

Rigshospitalet, Denmark

研究点 (1)

Loading locations...

相似试验